Quilizumab
Humanized (from mouse) | |
|---|---|
| Target | IGHE |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10046N1728O2023S44 |
| Molar mass | 146082.49 g·mol−1 |
Quilizumab (
INN) is a humanized monoclonal antibody designed for the treatment of asthma.[1] It binds to IGHE.[2][3][4][5][6][7]
This drug was developed by Genentech.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Quilizumab, American Medical Association.
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- PMID 27567329.
- PMID 26993628.
- S2CID 41593528.
- PMID 29290750.
- S2CID 51710078.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |